Cerus Corp CERS:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 01/27/23 EST
3.12UNCH (UNCH)
Volume
3,426
Close
3.12quote price arrow up+0.02 (+0.65%)
Volume
986,530
52 week range
2.53 - 6.00
Loading...
  • Open3.06
  • Day High3.15
  • Day Low3.06
  • Prev Close3.10
  • 52 Week High6.00
  • 52 Week High Date03/01/22
  • 52 Week Low2.53
  • 52 Week Low Date01/09/23

Key Stats

  • Market Cap553.553M
  • Shares Out177.42M
  • 10 Day Average Volume1.56M
  • Dividend-
  • Dividend Yield-
  • Beta0.97
  • YTD % Change-14.52

KEY STATS

  • Open3.06
  • Day High3.15
  • Day Low3.06
  • Prev Close3.10
  • 52 Week High6.00
  • 52 Week High Date03/01/22
  • 52 Week Low2.53
  • 52 Week Low Date01/09/23
  • Market Cap553.553M
  • Shares Out177.42M
  • 10 Day Average Volume1.56M
  • Dividend-
  • Dividend Yield-
  • Beta0.97
  • YTD % Change-14.52

RATIOS/PROFITABILITY

  • EPS (TTM)-0.22
  • P/E (TTM)-14.29
  • Fwd P/E (NTM)-15.37
  • EBITDA (TTM)-27.945M
  • ROE (TTM)-49.97%
  • Revenue (TTM)187.082M
  • Gross Margin (TTM)59.95%
  • Net Margin (TTM)-20.48%
  • Debt To Equity (MRQ)95.37%

EVENTS

  • Earnings Date02/20/2023(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Cerus Corp

 

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
Cerus Corporation is a biomedical products company. It is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, which is based on its technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives, such as plasma, platelets...
Daniel Swisher Jr.
Independent Chairman of the Board
William Greenman
President, Chief Executive Officer, Director
Vivek Jayaraman
Chief Operating Officer
Kevin Green CPA
Chief Financial Officer, Vice President - Finance
Chrystal Menard J.D.
Chief Legal Officer, General Counsel
Address
2550 STANWELL DRIVE
Concord, CA
94520
United States

Top Peers

SYMBOLLASTCHG%CHG
ANIK
Anika Therapeutics Inc
30.66-0.79-2.51%
SRDX
Surmodics Inc
26.68+0.33+1.25%
QIPT
Quipt Home Medical Corp
5.94+0.04+0.68%
SMTI
Sanara Medtech Inc
42.30+0.56+1.34%
ANGO
AngioDynamics Inc
12.99-0.01-0.08%